Bristol Myers Squibb: cross-border access for the specialty portfolio

Quick orientation

Bristol-Myers Squibb Company (BMS) is a US-headquartered pharmaceutical company based in New York City and Princeton, New Jersey. The 2019 acquisition of Celgene moved BMS's center of gravity decisively into hematology and immunology; the 2020 acquisition of MyoKardia added precision cardiovascular. BMS's specialty footprint is anchored in immuno-oncology (Opdivo, Yervoy, Opdualag, Krazati), hematology (Reblozyl, Inrebic, Onureg, Abecma CAR-T, Breyanzi CAR-T, Pomalyst, Revlimid legacy), cardiovascular (Eliquis co-marketed with Pfizer; Camzyos for hypertrophic cardiomyopathy), immunology (Zeposia, Sotyktu, Orencia), and rare disease.

For cross-border named-patient programs, the BMS hematology franchise (Reblozyl in transfusion-dependent anemia, Pomalyst in multiple myeloma) and the precision cardiovascular product Camzyos generate the highest single-product volumes at Reserve Meds intake.

Portfolio in cross-border NPP scope

Opdivo (nivolumab) and Yervoy (ipilimumab)

Anti-PD-1 (Opdivo) and anti-CTLA-4 (Yervoy) monoclonal antibodies, used singly and in combination across melanoma, non-small-cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, urothelial carcinoma, esophageal cancer, gastric cancer, classical Hodgkin lymphoma, and other indications. US WAC for the Opdivo flat 480mg every-four-weeks adult schedule runs above $25,000 per dose. Cross-border requests cluster around newer combination indications and the perioperative adjuvant settings that have not yet been added locally.

Reblozyl (luspatercept)

Erythroid maturation agent approved for anemia in adult beta-thalassemia requiring red-blood-cell transfusions and for anemia in lower-risk MDS. Cross-border demand from beta-thalassemia patients in MENA and India is significant where the locally registered indication is narrow or where the patient prefers the FDA-labeled US-sourced product.

Camzyos (mavacamten)

First-in-class cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy. US WAC is in the multi-tens-of-thousands per year range. International requests come from HCM patients in MENA and India where the diagnosis has been confirmed by echocardiography or cardiac MRI but no on-label disease-modifying option is locally available.

Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel)

BCMA-directed (Abecma) and CD19-directed (Breyanzi) autologous CAR-T cell therapies for relapsed and refractory multiple myeloma and large B-cell lymphoma respectively. Reserve Meds does not coordinate autologous CAR-T cross-border because of the apheresis-to-manufacturing logistics anchored to a US site; we redirect those inquiries to medical-travel pathway documentation.

Inrebic (fedratinib)

JAK2 inhibitor approved for intermediate-2 and high-risk primary or secondary (post-PV or post-ET) myelofibrosis. International requests come from MF patients in MENA and India who have failed ruxolitinib and need a second-line JAK inhibitor option.

Pomalyst, Revlimid, Onureg

The BMS-Celgene immunomodulatory hematology franchise. Pomalyst is approved for relapsed and refractory multiple myeloma and AIDS-related Kaposi sarcoma. Revlimid is approved across multiple myeloma, mantle cell lymphoma, follicular lymphoma, and MDS. Onureg is oral maintenance for AML in first complete remission. Cross-border requests cluster around triple-class refractory myeloma patients and AML maintenance.

Sotyktu (deucravacitinib) and Zeposia (ozanimod)

Sotyktu is an oral TYK2 inhibitor for moderate to severe plaque psoriasis; Zeposia is an oral S1P modulator for relapsing MS and moderately to severely active ulcerative colitis. International requests come from patients in the Gulf and India preferring oral therapy over biologics, and from UC patients where Zeposia has not yet been added to the local label.

Eliquis (apixaban, co-marketed with Pfizer)

Direct factor Xa inhibitor approved for stroke prophylaxis in non-valvular atrial fibrillation, VTE treatment and prophylaxis. Cross-border requests are typically for the higher-strength tablets where local supply gaps exist.

Why patients route BMS products through cross-border NPP

Three patterns dominate. First, the Reblozyl beta-thalassemia indication is one of the few disease-modifying options globally for transfusion-dependent thalassemia anemia, and MENA registration timing has lagged FDA approval. Second, Camzyos is too new in obstructive HCM for most non-US labels to have caught up. Third, the hematology immunomodulatory franchise (Pomalyst, Revlimid) requires REMS-equivalent dispensing controls; Reserve Meds operates within the US REMS framework at the dispensing pharmacy level while coordinating cross-border delivery under the patient's destination country regulatory pathway.

The BMS Patient Assistance Foundation and the BMS Access Support program are restricted to US residents. International patients route as cash-pay.

Manufacturer engagement posture

Reserve Meds coordinates BMS-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized BMS distributor; we are an independent named-patient program coordinator. All Reserve Meds orders are cash-pay at firm-quote pricing.

For BMS market access teams: Reserve Meds carries structured demand visibility across the Reblozyl, Camzyos, and hematology immunomodulatory franchises. If your group is sizing pre-registration demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the BMS portfolio

Reblozyl concentrates in India, Egypt, Saudi Arabia, and the UAE where beta-thalassemia patient populations are largest. Camzyos is heaviest in the Gulf and India where echocardiography-confirmed HCM cohorts route through cardiology centers of excellence. The myeloma and lymphoma franchise tracks oncology specialist concentration.

What Reserve Meds provides

For every BMS product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a BMS product and want a firm quote can start a request below.

Start a request for a BMS product

Next step for BMS teams

If you are on the BMS access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.